Pharmacokinetics of High-Dose Cytarabine and its Deamination Product-A Reappraisal

References

• Plunkett W., Iacoboni S., Estey E., Danhauser L., Liliemark J.O., Keating M.J. Pharmacologically directed araC therapy for refractory leukemia. Seminars in Oncology 1985; 12: 20–30, (Suppl 3)
   PubMed Web of Science ®Google Scholar
• Estey E., Plunkett W., Dixon D., Keating M., McCredie K., Freireich E.J. Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia 1987; 1: 580–583
   PubMed Web of Science ®Google Scholar
• Raza A., Preisler H.D., Browman G.P., Larson R.A., Rustum Y.M., Goldberg J., Vogler R., Miller K.A., Bennett J., Kukla C. Long-term outcome of patients with acute myelogenous leukemia: the role of maintenance therapy, consolidation therapy and the predictive value of two in vitro assays. Leukemia and Lymphoma 1993; 10: 57–66
   PubMed Web of Science ®Google Scholar
• Chandrasekaran B., Capizzi R.L., Kute T.E., Morgan T., Dimling J. Modulation of the metabolism and pharmacokinetics of 1-β-D-arabinofuranosylcytosine by 1-β-D-arabinofuranosyluracil in leukemic mice. Cancer Research 1989; 49: 3259–3266
   PubMed Web of Science ®Google Scholar
• Chandrasekaran B., Kute T.E., Capizzi R.L. Deoxypyrimidine-induced inhibition of the cytokinetic effects of 1-β-D-arabinofuranosyluracil. Cancer Chemotherapy and Pharmacology 1992; 29: 455–460
   PubMed Web of Science ®Google Scholar
• Yang J.L., Cheng E.H., Capizzi R.L., Cheng Y.C., Kute T. Effect of uracil arabinoside on metabolism and cytotoxicity of cytosine arabinoside in L5178Y murine leukemia. Journal of Clinical Investigation 1985; 75: 141–146
   PubMed Web of Science ®Google Scholar
• Hiddemann W. Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens. Annals of Hematology 1991; 62: 119–128
   PubMed Web of Science ®Google Scholar
• Jamieson G.P., Snook M.B., Wiley J.S. Saturation of intracellular cytosine arabinoside triphosphate accumulation in human leukemic blast cells. Leukemia Research 1990; 14: 475–479
   PubMed Web of Science ®Google Scholar
• White J.C., Rathmell J.P., Capizzi R.L. Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells. Journal of Clinical Investigation 1987; 79: 380–387
   PubMed Web of Science ®Google Scholar
• Capizzi R.L., Yang J.L., Cheng E., Bjornsson T., Sahasrabudhe D., Tan R.S., Cheng Y.C. Alteration of the pharmacokinetics of high-dose araC by its metabolite, high araU in patients with acute leukemia. Journal of Clinical Oncology 1983; 1: 763–771
   PubMed Web of Science ®Google Scholar
• Kreis W., Lesser M., Budman D.R., Arlin Z., DeAngelis L., Baskind P., Feldman E.J., Akerman S. Phenotypic analysis of 1-β-D-arabinofuranosylcytosine deamination in patients treated with high doses and correlation with response. Cancer Chemotherapy and Pharmacology 1992; 30: 126–130
   PubMed Web of Science ®Google Scholar
• Burk M., Volmer M., Fartash K., Schneider W. Ion-pair liquid chromatography of cytarabine and uracil-arabinoside in human plasma. Arzneimittelforschung/Drug Research 1995; 45: 616–619
   PubMed Web of Science ®Google Scholar
• Heinzel G., Woloszczak R., Thomann P. TopFit 2.0; pharmacokinetic and pharmacodynamic data analysis system for the PC. Fischer, Stuttgart 1993
   Google Scholar
• Tanswell P., Koup J. TopFit: a PC-based pharmacokinetic/pharmacodynamic data analysis program. International Journal of Clinical Pharmacology, Therapy and Toxicology 1993; 31: 514–520
   PubMedGoogle Scholar
• Gibaldi M., Perrier D. Pharmacokinetics, 2nd edn. Marcel Dekker, New York 1982
   Google Scholar
• Peters W.G., Willemze R. Cytarabine and CNS toxicity. Journal of Clinical Oncology 1992; 10: 169
   PubMed Web of Science ®Google Scholar
• Damon L.E., Plunkett W., Linker C.A. Plasma and cerebrospinal fluid pharmacokinetics of 1-β-D-arabinofuranosylcytosine and 1-β-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-β-D-arabinofuranosylcytosine. Cancer Research 1991; 51: 4141–4145
   PubMed Web of Science ®Google Scholar
• Plunkett W., Liliemark J.O., Adams T.M., Nowak B., Estey E., Kantarjian H., Keating M.J. Saturation of 1-β-D-arabinofuranosylcytosine 5′-triphos-phate accumulation in leukemia cells during high-dose 1-β-D-arabinofuranosylcytosine therapy. Cancer Research 1987; 47: 3005–3011
   PubMed Web of Science ®Google Scholar
• Hiddemann W., Schleyer E., Unterhalt M., Zühlsdorf M., Rolf C., Reuter C., Kewer U., Uhrmeister C., Wormann B., Büchner T. Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells. Leukemia 1992; 6: 1273–1280
   PubMed Web of Science ®Google Scholar
• Zimmerman C.L. The disposition of cytosine arabinoside and its metabolite after single doses to rabbits. Biopharmaceutics and Drug Disposition 1990; 11: 121–129
   PubMed Web of Science ®Google Scholar
• Liliemark J.O., Plunkett W., Dixon D.O. Relationship of 1-β-D-arabinofuranosylcytosine in plasma to 1-β-D-arabinofuranosylcytosine 5′-triphosphate levels in leukemic cells during treatment with high-dose 1-β-D-arabinofuranosylcytosine. Cancer Res 1985; 45: 5952–5957
   PubMed Web of Science ®Google Scholar
• Rustum Y.M., Slocum H.K., Wang G., Bakshi D., Kelly E., Buscaglia D., Wrzosek C., Early A.P., Preisler H. Relationship between plasma araC and intracellular Ara-CTP pools under conditions of continuous infusion and high-dose araC treatment. Medical and Pediatric Oncology 1982; 10: 33–43, (Suppl 1)
   PubMedGoogle Scholar
• Fleming R.A., Capizzi R.L., Rosner G.L., Oliver L.K., Smith S.J., Schiffer C.A., Silver R.T., Peterson B.A., Weiss R.B., Omura G.A. Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study. Cancer Chemotheraphy and Pharmacology 1995; 36: 425–430
   PubMed Web of Science ®Google Scholar
• Allerheiligen S., Johnson R., Hatcher B., Freeman K., Tarassoff P., Voi M., Dorr A. Gemcitabine pharmacokinetics are influenced by gender, body surface area (BSA), and duration of infusion. Proceedings of the American Society of Clinical Oncology 1994; 13: 136, (Abstr. 339)
   Google Scholar
• Rubin E.H., Andersen J.W., Berg D.T., Schiffer C.A., Mayer R.J., Stone R.M. Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia. Journal of Clinical Oncology 1992; 10: 948–953
   PubMed Web of Science ®Google Scholar